ANL

NASDAQ 已收盘

Adlai Nortye Group

9.06 USD
▲+0.32+3.66%
盘后 10.53 0.00%
2026-11-19
市值
$550.60M
市盈率
—
EPS
-0.56
股息率
—
52 周区间
0.88 – 17.25
成交量
216.07K
Beta
1.41
目标价
29.50
52W 低 0.8852W 高 17.25
价格走势

公司简介

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (αPD-L1 x CD86 variant x LAG3 variant) t...